Varenicline, marketed globally under various brand names (most notably as Chantix/Champix prior to its patent expiry and subsequent recall issues, leading to generic availability), is a highly effective medication for smoking cessation. Its mechanism of action, as a partial agonist of the α4​β2​ nicotinic acetylcholine receptor, helps reduce cravings and withdrawal symptoms, while simultaneously blocking the rewarding effects of nicotine. Despite past challenges, the demand for Varenicline remains robust as a crucial tool in public health initiatives aimed at reducing global smoking rates. For Varenicline suppliers, whether of Active Pharmaceutical Ingredient (API) or finished dosage forms (FDF), identifying and connecting with global buyers is essential for market penetration and sustained…